Details
This request assessed utilization patterns for SGLT2 inhibitors including canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sitagliptin. Patients were assessed with an inclusion requirement of Type 1 diabetes mellitus diagnosis in addition to evidence of rapid insulin use, with an exclusion requirement of evidence of use of oral antidiabetics not including metformin. Patients were assessed separately with an inclusion requirement of Type 2 diabetes mellitus diagnosis in addition to evidence of use of oral antidiabetics including metformin, with an exclusion requirement of Type 1 diabetes mellitus diagnosis.
The study period includes data from January 1, 2010 to September 30, 2020. We executed this request on Merative™ MarketScan® Research Databases on September 9, 2021.